Skip to main content

Fluarix Quadrivalent FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 28, 2020.

FDA Approved: Yes (First approved December 14, 2012)
Brand name: Fluarix Quadrivalent
Generic name: influenza virus vaccine, inactivated
Dosage form: Injection
Company: GlaxoSmithKline
Treatment for: Influenza Prophylaxis

Fluarix Quadrivalent is an inactivated influenza virus vaccine indicated for the prevention of influenza disease in people aged 6 months and older.

Development timeline for Fluarix Quadrivalent

Jan 11, 2018Approval GSK Receives FDA Approval for Expanded Indication for Fluarix Quadrivalent (Influenza Vaccine) for Persons 6 Months and Older
Dec 17, 2012Approval FDA Approves GlaxoSmithKline's Fluarix Quadrivalent - Four-strain Seasonal Influenza Vaccine for Use in the U.S.
Oct 19, 2009Approval FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use
Aug 31, 2005Approval Fluarix GlaxoSmithKline - Treatment for Influenza Vaccination
May 25, 2005GlaxoSmithKline Submits Biologics License Application for FDA Approval of Fluarix

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.